MXPA02000242A - Analogos de 2-aminoindano. - Google Patents

Analogos de 2-aminoindano.

Info

Publication number
MXPA02000242A
MXPA02000242A MXPA02000242A MXPA02000242A MXPA02000242A MX PA02000242 A MXPA02000242 A MX PA02000242A MX PA02000242 A MXPA02000242 A MX PA02000242A MX PA02000242 A MXPA02000242 A MX PA02000242A MX PA02000242 A MXPA02000242 A MX PA02000242A
Authority
MX
Mexico
Prior art keywords
aminoindane
analogs
formula
compounds
metabotropic glutamate
Prior art date
Application number
MXPA02000242A
Other languages
English (en)
Inventor
Kenneth Curry
Original Assignee
Prescient Neuropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prescient Neuropharma Inc filed Critical Prescient Neuropharma Inc
Publication of MXPA02000242A publication Critical patent/MXPA02000242A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente investigacion se refiere a analogos terapeuticamente activos de 2 aminoindano de formula (I); tambien se provee un metodo para preparar compuestos de formula (I), y composiciones farmaceuticas que comprenden los compuestos; los compuestos novedosos actuan como moduladores de receptores de glutamato metabotropico y, como tales, son utiles para tratar enfermedades del sistema nervioso central relacionadas al sistema receptor de glutamato metabotropico.
MXPA02000242A 1999-06-30 2000-06-30 Analogos de 2-aminoindano. MXPA02000242A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2276798 1999-06-30
PCT/CA2000/000770 WO2001002342A1 (en) 1999-06-30 2000-06-30 2-aminoindane analogs

Publications (1)

Publication Number Publication Date
MXPA02000242A true MXPA02000242A (es) 2004-09-10

Family

ID=4163674

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02000242A MXPA02000242A (es) 1999-06-30 2000-06-30 Analogos de 2-aminoindano.

Country Status (6)

Country Link
US (1) US7034055B1 (es)
EP (1) EP1194400A1 (es)
AU (1) AU5667900A (es)
MX (1) MXPA02000242A (es)
NZ (1) NZ516467A (es)
WO (1) WO2001002342A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
AU2002307049A1 (en) * 2001-04-02 2002-10-15 Brown University Research Foundation Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
NZ533699A (en) * 2001-12-27 2006-05-26 Taisho Pharmaceutical Co Ltd 6-fluorobicyclo[3.1.0]hexane derivatives
WO2005000790A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体
WO2006121919A2 (en) * 2005-05-05 2006-11-16 Massachusetts Institute Of Technology Methods of treating obsessive compulsive disorder
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
GB201615191D0 (en) * 2016-09-07 2016-10-19 Takeda Pharmaceuticals Co Novel compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3494915A (en) 1967-07-28 1970-02-10 American Home Prod 6-(indan - 2 - amino - 2 - carboxamido) and 6 - (1,2,3,4 - tetrahydronaphthalene - 2-amino - 2 - carboxamido) penicillanic acids
US3532744A (en) 1967-07-28 1970-10-06 American Home Prod 1- and 2-amino substituted indane and tetralene carboxylic acids
BE755090A (fr) 1969-08-22 1971-02-22 American Home Prod Acides penicillaniques
US3704312A (en) 1970-10-30 1972-11-28 American Home Prod Bialicyclic amino acids
US3746495A (en) 1971-06-01 1973-07-17 American Home Prod Anti-ulcer therapy
US4291050A (en) 1979-06-21 1981-09-22 Merck & Co., Inc. 6,7-Disubstituted-2 or 2,2-substituted-5-substituted-1-indanones
EP0077122B1 (en) 1981-09-15 1986-05-07 Imperial Chemical Industries Plc Amino-substituted tetralins and related homocyclic compounds
US4500713A (en) * 1982-09-23 1985-02-19 Usv Pharmaceutical Corporation Therapeutic dipeptides
DK34086A (da) 1985-01-23 1986-07-24 Abbott Lab Peptidylaminodioler
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4775695A (en) 1987-06-01 1988-10-04 Merck & Co., Inc. Substituted amidinoalkoxy and amidinoalkylamino indanones and salts thereof
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1991012266A1 (en) 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
NZ237443A (en) 1990-04-10 1993-11-25 Asta Medica Ag Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
CZ287406B6 (cs) 1991-11-05 2000-11-15 Smithkline Beecham Corporation Indanové a indenové deriváty, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
ES2086151T3 (es) 1992-04-28 1996-06-16 Hoechst Ag Procedimiento para la preparacion de indanonas sustituidas.
TW306910B (es) 1992-09-11 1997-06-01 Hoechst Ag
US5378838A (en) 1993-01-13 1995-01-03 Merck & Co., Inc. Benzodiazepine cholecystokinin antagonists
FR2700540B1 (fr) 1993-01-15 1995-02-17 Irj alpha-méthyl-(R)-tryptophyl-arylcycloalkylalkylamides ligands aux récepteurs des gastrines, leur préparation et leur utilisation en thérapeutique.
AU1106195A (en) 1994-11-09 1996-06-06 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US5648336A (en) 1994-11-18 1997-07-15 University Of Colorado Bradykinin antagonist peptides containing indane-substituted amino acids
US5834431A (en) 1995-09-08 1998-11-10 Cortech, Inc. Des-Arg9 -BK antagonists
ZA969485B (en) * 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
JP2000514838A (ja) 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
US5948807A (en) 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides

Also Published As

Publication number Publication date
AU5667900A (en) 2001-01-22
US7034055B1 (en) 2006-04-25
WO2001002342A1 (en) 2001-01-11
NZ516467A (en) 2004-03-26
EP1194400A1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
MXPA02011053A (es) Compuestos novedosos de carboxi amino espiro (2,4)heptano y derivados de los mismos.
MXPA02001340A (es) Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
HU9602522D0 (en) Heterocyclic compounds, their preparation and use
UA87653C2 (en) 1,2,4-oxadiazols as modulators of receptor-5 for metabotropic glutamate
SE9503924D0 (sv) Novel opioid peptides
GEP20033114B (en) Biphenyl Sulfonamides as Dual Angiotensin Endothelin Receptor Antagonists, Method for Their Production and Pharmaceutical Compositions Containing the Same
MXPA02000242A (es) Analogos de 2-aminoindano.
UA34416C2 (uk) Похідні хроману, активні стосовно 5-нт рецептора, спосіб їх одержання та проміжні сполуки
SE0100569D0 (sv) New compounds
TW430662B (en) Benzene-condensed hetero ring derivatives and their uses
NZ522195A (en) Novel amino carboxy alkyl derivatives of barbituric acid, preparation process and use for treating central nervous system disorders thereof
BR9910130A (pt) Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação
HK1046902A1 (zh) 新型哌嗪基烷基硫代嘧啶衍生物，包含該衍生物的藥物組合物以及製備該活性物質的方法
WO2001002340A3 (en) Novel aminoindanes
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
UA66866C2 (uk) Синтез морфолінових похідних
NO308658B1 (no) Sammenføyde isoquinoliner som dopamin-reseptor-ligander
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
FR2724933B1 (es)
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
HU9503099D0 (en) New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
AU2287197A (en) Heterocyclic compounds and their preparation and use
WO2004024709A3 (en) Xanthenyl cubane analogs with activity at the metabotropic glutamate receptors